The Magazine of Corporate Responsibility

Tag Archive for ‘Off-label Marketing’

First Amendment Claims Seen as Rx for Drug Makers, Headache for Consumers

Decisions in recent legal cases are fueling debate about whether the First Amendment’s protection of commercial speech could undermine the FDA’s ability to prevent drug marketing abuses. Some worry that changing political dynamics – especially the anti-regulatory aims of the Trump administration and Republican-dominated Congress – could free drug makers to push the boundaries of the law.

Lawsuits Say Pharma Illegally Paid Doctors to Push Their Drugs

Drug companies say the millions of dollars they pay physicians for speaking and consulting justly compensates them for the laudable work of educating their colleagues. But ProPublic reports that a series of lawsuits brought by former employees of those companies allege the money often was used for illegal purposes — financially rewarding doctors for prescribing their brand-name medications.

Novartis to Pay $72.5 Million to Settle Illegal Marketing Charges

The charges involved off-label marketing of the cystic fibrosis drug TOBI. Under the agreement the federal government will get $43.5 million and 10 U.S. states will share $29 million. Three former employees will share $7.825 million to settle their whistleblower lawsuit.

AstraZeneca to Pay $520 Million to Settle Illegal Marketing Charges

The settlement involves civil charges that from 2001 through 2006 the pharmaceutical company illegally marketed the anti-psychotic drug Seroquel for so-called “off-label” uses not approved by the U.S. Food and Drug Administration.